Development of functional lipid nanoparticles for RNA interference-based therapy
| Project/Area Number |
16K08201
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | University of Shizuoka |
|---|
Principal Investigator |
Tomohiro Asai 静岡県立大学, 薬学部, 教授 (00381731)
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 脂質ナノ粒子 / RNA干渉 / オートファジー / siRNA / verteporfin / DDS / 薬学 / ドラッグデリバリー |
|---|
| Outline of Final Research Achievements |
Small interfering RNA (siRNA) capable of inducing gene silencing is a promising drug candidate to address unmet medical needs. However, siRNA is difficult to induce gene silencing without an appropriate delivery vehicle. The establishment of effective delivery systems is one of the most important tasks to develop RNA interference (RNAi)-based drugs. Functional lipid nanoparticles are attractive and promising vectors for RNAi therapy. In the present study, we developed novel lipid nanoparticles containing a possible RNAi enhancer for cancer treatment. Our findings provide new insights into the design of effective lipid nanoparticles for RNAi therapy.
|
| Academic Significance and Societal Importance of the Research Achievements |
RNA干渉薬をアプタマー医薬や抗体医薬と比較すると、細胞内タンパク質が創薬ターゲットになるという利点が大きく、DDSの技術革新次第では数多くの画期的医薬品が創出される可能性がある。つまり、RNAを安全に患部に運搬するシステムが確立されれば、アンドラッガブル問題の解消へと繋がり、医療の進歩に大きく貢献できる。本研究の成果は、RNA干渉薬開発に必要なDDSについて重要な基礎的知見を与えるものであり、その学術的意義は大きい。
|
Report
(4 results)
Research Products
(61 results)
-
-
-
[Journal Article] Shea KJ. Sequestering and inhibiting a vascular endothelial growth factor in vivo by systemic administration of a synthetic polymer nanoparticle.2019
Author(s)
Koide H, Yoshimatsu K, Hoshino Y, Ariizumi S, Okishima A, Ide T, Egami H, Hamashima Y, Nishimura Y, Kanazawa H, Miura Y, Asai T, Oku N,
-
Journal Title
J. Control. Release.
Volume: 295
Pages: 13-20
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Targeted Therapy for Acute Autoimmune Myocarditis with Nano-Sized Liposomal FK506 in Rats.2017
Author(s)
Okuda K, Fu HY, Matsuzaki T, Araki R, Tsuchida S, Thanikachalam PV, Fukuta T, Asai T, Yamato M, Sanada S, Asanuma H, Asano Y, Asakura M, Hanawa H, Hao H, Oku N, Takashima S, Kitakaze M, Sakata Y, Minamino T.
-
Journal Title
PLoS One.
Volume: 11
Issue: 8
Pages: e0160944-e0160944
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Journal Article] Non-invasive evaluation of neuroprotective drug candidates for cerebral infarction by PET imaging of mitochondrial complex-1 activity2016
Author(s)
Tatsuya Fukuta, Tomohiro Asai, Takayuki Ishii, Hiroyuki Koide, Chiaki Kiyokawa, Masahiro Hashimoto, Takashi Kikuchi, Kosuke Shimizu, Norihiro Harada, Hideo Tsukada, Naoto Oku
-
Journal Title
Scientific Reports
Volume: 6
Issue: 1
Pages: 30127-30127
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Simple and efficient approach for siRNA encapsulation into PCLs by freeze-thawing method.2016
Author(s)
Ayaka Okamoto, Hiroyuki Koide, Hiroki Tsuchida, Hidenori Ando, Saki Ariizumi, Chiaki Kiyokawa, Masahiro Hashimoto, Tomohiro Asai, Takehisa Dewa, Naoto Oku
Organizer
International Conference on Nanomedicine and Nanobiotechnology
Place of Presentation
Paris, France
Related Report
Int'l Joint Research
-
-
-
-
-
-
